Amends GS Chapter 90 by adding a new article, Article 4D, prescription Drug Transparency.

Enacts GS 90-85.55, defining eight terms, including generic drug, interested parties, manufacturer, prescriber, prescription drug, prescription order, Secretary (Department of Health and Human Services Secretary), and substantial price increase. Defines interested parties as state agencies that purchase prescription drugs or employ prescribers, health insurance companies, health care service plan providers, and pharmacy benefit managers. Defines manufacturer as entities or their agents that are involved in a host of listed ways with preparation of brand-name or generic drugs but does not include an entity engaged in preparation or dispensing these drugs pursuant to a prescription. Defines substantial price increase as any increase in price charged by a manufacturer for a prescription drug that would increase the cost of the drug by 10% or more over 12 months.

Enacts GS 90-85.56, requiring a manufacturer to notify all interested parties of upcoming substantial price increases at least 60 days before the increase and provides a list of disclosures manufacturers must provide to the interested parties within 30 days after notice is given. Requires a manufacturer to notify all interested parties of the price of any new prescription drug within three days after it receives approval by the US Food and Drug Administration and provides a list of disclosures manufacturers must provide to the interested parties within 30 days after notice is given. Requires a manufacturer or its agent to disclose to a prescriber if any ingredient in a prescription drug is known to pose a risk of dependency in humans if they are meeting or otherwise communicating with the prescriber to market the drug.

Enacts GS 90-85.57, requiring the Secretary to assess a civil penalty, with a maximum of $1,000 per day, against a manufacturer that fails to report information required under GS 66-462(a) and (b). Remits proceeds from any penalties to the Civil Penalty and Forfeiture Fund.

Enacts GS 90-85.88, clarifying that nothing in this Article is a price limitation.

Enacts GS 90-85.59, requiring the Secretary to develop a data collection plan to collect manufacturer data related to cost and pricing of prescription drugs. Requires Secretary to submit an implementation plan regarding these requirements and any other findings to the Joint Legislative Oversight Committee on Health and Human Services by February 1, 2026. Requires Secretary to implement an online portal granting public access to notifications, reports, and other disclosures required by this Article. Requires annual report by Secretary to the Joint Legislative Oversight Committee on Health and Human Services beginning December 1, 2026, with the listed information about prescription drugs.

Effective October 1, 2025.